Anvisa expands testing of coronavirus vaccines in Brazil


posted on 09/23/2020 16:15

(credit: Ed Alves / CB / DA Press)

After Johnson & Johnson announced on Wednesday (9/23) that it will begin phase 3 testing of the vaccine produced by the pharmaceutical company Janssen-Cilag, which belongs to the group, the National Health Surveillance Agency (Anvisa) confirmed the participation of more four states in the immunizer tests. Federal District, Mato Grosso do Sul, Mato Grosso and Santa Catarina will be part of the vaccine study.

The tests were already authorized to take place in seven Brazilian states (SP, RJ, RS, PR, MG, BA, RN). In total, 7 thousand volunteers will be tested. The Johnson & Johnson vaccine study was authorized on August 18. Only one dose of the vaccine is needed. Volunteers between 18 and 55 years old participate in the tests.

On Wednesday, the agency also authorized an increase in the number of volunteers in studies of the Coronavac vaccine, produced by the Chinese company Sinovac in partnership with the Butantan Institute. A further 4,060 volunteers were included in the study, which now has 13,060 Brazilians.

In addition, the study of the Chinese vaccine will also be carried out in Mato Grosso do Sul and Mato Grosso, in addition to São Paulo, Rio Grande do Sul, Minas Gerais, Paraná and the Federal District.

According to the governor of São Paulo, João Doria (PSDB), the Coronavac phase 3 study pointed out safety and effectiveness to proceed with development. The first batch of the Chinese vaccine against covid-19 will arrive in Brazil next month and the expectation is that immunization in residents of São Paulo will start this year.


Please enter your comment!
Please enter your name here